Search Results 431-440 of 18359 for alopecia

1. A Study to Evaluate the Effectiveness of M7824 Monotherapy in Locally Advanced or Metastatic Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - Mayo Clinic

   0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade ≤ 2 is acceptable. Clinically significant ...

2. A Study of ABBV-085, an Antibody Drug Conjugate, for Patients with Advanced Solid Cancer Tumors - Mayo Clinic

   Unresolved adverse events ≥ Grade 2 from prior anticancer therapy, except for alopecia; Has ongoing hemolysis; Major surgery within ≤ 28 days prior to the ...

3. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia. ... alopecia) not requiring systemic treatment, or ...

4. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

   ... alopecia, are excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to axatilimab or olaparib ...

5. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

6. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

   ... alopecia - Patients with uncontrolled intercurrent illness - Patients with >= grade 2 neuropathy within 14 days of registration - Patients with severe ...

7. Hydrochlorothiazide (oral route) - Side effects & dosage - Mayo Clinic

   Hydrochlorothiazide is also used to treat fluid retention (edema) that is caused by congestive heart failure, severe liver disease (cirrhosis), kidney disease, ...

8. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

9. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   NOTE: All toxicities from prior therapy must be ≤ Grade 1 (or ≤ Grade 2 for peripheral neuropathy or alopecia). Impaired cardiovascular function or ...

10. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer - Mayo Clinic

    ... alopecia * Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease * Evidence of active and uncontrolled hepatitis B ...